Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. frebt

FrEBT

Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL Ltd. competitiveness and growth by validation of fractional EBT biomarker through new method of measurement and device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 FrEBT project word cloud

Explore the words cloud of the FrEBT project. It provides you a very rough idea of what is the project "FrEBT" about.

share    temperature    exhaled    specialisation    total    faster    competitiveness    phase1    worldwide    vulnerable    gps    diseases    prove    disruptive    innovation    sme    network    million    asia    comac    ip    doctors    innovative    validate    annually    lung    population    region    trials    diagnostic    niche    10    markets    bulgaria    feasibility    clinical    pulmonology    young    children    assessing    description    risk    socio    filling    financial    14    elderly    countries    5    380    fractional    painful    organization    stages    prognostic    morbidity    15    technological    monitoring    medical    ltd    oncology    cancer    outcome    mln    groups    device    biomarker    profitability    breath    healthcare    market    20    invasive    12    solution    organizational    alternative    commercial    inflammatory    bln    regions    118    launch    mortality    patients    diagnosis    eu28    deaths    precise    saving    workforce    people    managerial    obstructive    respiratory    economic    full    causing    pulmonary    service    lives    global    specialists   

Project "FrEBT" data sheet

The following table provides information about the project.

Coordinator		 COMAC MEDICAL LTD 

Organization address
address: 131 ODRIN STR AP 22
city: SOFIA
postcode: 1303
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Bulgaria [BG]
 Project website http://comac-medical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMAC MEDICAL LTD BG (SOFIA) coordinator 50˙000.00

Map

 Project objective

The innovation project objectives are to: 1/prove through a feasibility study the potential to validate the Fractional Exhaled Breath Temperature, via new viable and disruptive technological device, as a diagnostic, prognostic and monitoring biomarker for inflammatory and obstructive pulmonary diseases; 2/enhance the competitiveness and profitability of the full- service clinical research organization COMAC MEDICAL Ltd., operating via own network of partners in 14 countries from 3 European regions with population of over 118 mln. The commercial potential of the innovative solution is that it is a best alternative of the existing methods on market, saving great number of diagnosis‘ stages without any potential risk for the patients, being more precise, user friendly, non-invasive, less painful, faster, cost effective, covering vulnerable groups of children, young and elderly people, saving lives, increasing workforce capabilities. It is a response to the EU wide and global challenges related to the respiratory diseases causing high level of morbidity and mortality–at about 1 million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of € 380 bln. The expected SME growth is 20%, leading to specialisation in Pulmonology and Oncology and filling a market niche. The SME will launch into new markets in Europe and Asia, increasing its market share in clinical trials - 12-15% in Bulgaria;10% in Europe and 2-5% worldwide. The outcome of the Phase1 project is a feasibility study, assessing the socio-economic, commercial, technical aspects of the innovation, based on 6 steps of activities on: the Description of the innovative solution;Market/Technical Feasibility;Financial/Economic Feasibility; Organizational/Managerial Feasibility;Risk assessment;IP Management. The targeted users are the patients through the healthcare systems and the doctors, specialists in respiratory diseases and lung cancer as well as the GPs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FREBT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FREBT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More